Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb for Second Lead Compound in Cardiovascular RNA Collaboration
核心洞察
Atrium Therapeutics (搜索) earned a $15 million milestone payment from Bristol Myers Squibb (搜索) for successfully delivering a second lead compound targeting an undisclosed cardiology indication.
The payment stems from a global licensing and research collaboration focused on RNA-based therapies for multiple cardiovascular indications.
Atrium is eligible for up to approximately $1.35 billion in R&D milestones, $825 million in commercial milestones, and tiered royalties up to low double-digits on net sales.
Atrium Therapeutics (搜索), Inc. (Nasdaq: RNA), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced on Aug. 13, 2026 that it has earned another $15 million milestone payment from Bristol Myers Squibb (搜索) (NYSE: BMY). The payment was triggered by the successful delivery of a lead compound targeting an undisclosed cardiology indication under the companies' ongoing collaboration.
"Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, President and CEO of Atrium Therapeutics (搜索). "Advancing a second lead compound under our collaboration with Bristol Myers Squibb (搜索) reflects the strength and versatility of our RNA delivery platform, and it gives us continued momentum as we work together to bring novel therapies to patients and families facing significant unmet need."
Collaboration Terms and Financial Structure
The payment is made pursuant to Atrium's global licensing and research collaboration with Bristol Myers Squibb (搜索) (BMS), which is focused on the discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications. Under the terms of the agreement, Atrium is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. BMS will fund all future clinical development, regulatory and commercialization activities arising from the collaboration.
Atrium's RNA Delivery Platform
Atrium Therapeutics (搜索) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology — designed at Avidity Biosciences, Inc. — combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. This approach is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA).
The platform builds upon learnings from demonstrated delivery to skeletal muscle and applies them for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery.
Advancing Pipeline in Precision Cardiology
The milestone reflects continued momentum in Atrium's precision cardiology pipeline. Following the U.S. Food and Drug Administration's (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 (搜索) for PRKAG2 (搜索) (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial.
Beyond ATR 1072 (搜索), the Company's pipeline includes ATR 1086 (搜索) for PLN (phospholamban (搜索)) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.